Clinical Trial Search

Primary: Number of Total Lesions Detected on 89Zr-TLX250 PET/CT Versus 18FDG PET/CT — 264; 231 lesions

Primary: Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16 — 9.3; 37.2; 58.1…

Primary: Proportion of Subjects Who Achieve ≥75% Overall Improvement in Eczema Area and Severity Index (EASI) Score From Baseline to Week 16. — 9.8; 18.1; 12.5; 15.1 percentage…

Primary: Efficacy in Hip Fracture Patients Confirmed by DXA Scan. — 0; 4.75; 7.15; 9.08 PBO adjusted percent change — p=0.0032

Primary: The Proportion of Subjects With Adverse Events (AEs), Judged to be Probably or Definitely Related to the Investigational Product (IP), Within 90 Days After the First IP…

Primary: Change in Boston Carpal Tunnel Syndrome (BCTQ) Score — -0.5 score on a scale

Primary: Number of Participants With Adverse Events (AEs) — 1; 3; 3; 3 Participants

Primary: Percentage of Participants Achieving Endoscopic Improvement — 16.7 percentage of participants

Primary: Objective Response Rate (ORR): Percentage of Participants With Objective Response Per the Lugano Classification by Central Assessment — 92; 69 percentage of participants

Primary: Mean Percent Change in LDL-C From Baseline To Week 12 — -10.6; 8.2 percent change — p=<0.0001

Primary: Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 32; 36; 37; 43 Participants

Primary: Opioid Use: Proportion of Positive Urine Drug Screens (UDS) — 0.83; 0.67 Proportion of urine drug screens

Primary: Apnea-hypopnea Index [AHI] — -11.8; -2.3 events/hr; % change from baseline

Primary: Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) — -32.9; -10.4 percent…

Primary: To Evaluate the Efficacy of the Treatment — 1.9 Months